ADMA Biologics - ADMA Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1 year price targets for ADMA Biologics' shares. Their ADMA share price forecasts range from $4.50 to $6.00. On average, they anticipate the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price.
View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts.

ADMA Biologics' stock was trading at $3.88 at the beginning of the year. Since then, ADMA shares have decreased by 2.3% and is now trading at $3.79.
View the best growth stocks for 2023 here.

ADMA Biologics saw a decrease in short interest in January. As of January 15th, there was short interest totaling 12,050,000 shares, a decrease of 5.3% from the December 31st total of 12,720,000 shares. Based on an average daily volume of 3,290,000 shares, the short-interest ratio is currently 3.7 days.
View ADMA Biologics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADMA earnings forecast.

ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. The biotechnology company had revenue of $20.68 million for the quarter, compared to the consensus estimate of $18.58 million. ADMA Biologics had a negative net margin of 53.89% and a negative trailing twelve-month return on equity of 52.73%. During the same period in the previous year, the firm posted ($0.19) earnings per share.

ADMA Biologics issued an update on its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $153.00 million-$154.00 million, compared to the consensus revenue estimate of $148.95 million.

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.20%), UBS Group AG (0.28%), Swiss National Bank (0.24%), Raymond James & Associates (0.12%), First Hawaiian Bank (0.10%) and Raymond James Financial Services Advisors Inc. (0.08%). Insiders that own company stock include Adam S Grossman, Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen, Perceptive Advisors Llc and Young Kwon.
View institutional ownership trends.

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADMA stock can currently be purchased for approximately $3.79.

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $745.80 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

The company employs 527 workers across the globe.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for the company is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.